Theralase Technologies (Theralase Technologies) 3-Year EPS without NRI Growth Rate : 6.60% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Theralase Technologies 3-Year EPS without NRI Growth Rate?

Theralase Technologies's EPS without NRI for the three months ended in Dec. 2023 was $-0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 6.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 3.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Theralase Technologies was 21.60% per year. The lowest was -65.10% per year. And the median was -0.75% per year.

Competitive Comparison of Theralase Technologies's 3-Year EPS without NRI Growth Rate

For the Medical Devices subindustry, Theralase Technologies's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's 3-Year EPS without NRI Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's 3-Year EPS without NRI Growth Rate falls into.

Theralase Technologies 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Theralase Technologies (OTCPK:TLTFF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Theralase Technologies 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies (Theralase Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (OTCPK:TLTFF) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

TLT:Canada

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.